GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » Stock Based Compensation
中文

Biomark Diagnostics (Biomark Diagnostics) Stock Based Compensation

: $0.07 Mil (TTM As of Dec. 2023)
View and export this data going back to 2015. Start your Free Trial

Biomark Diagnostics's Stock Based Compensation for the three months ended in Dec. 2023 was $0.02 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 was $0.07 Mil.


Biomark Diagnostics Stock Based Compensation Historical Data

The historical data trend for Biomark Diagnostics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.62 0.32 - 0.24

Biomark Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.01 0.03 0.02 0.02

Biomark Diagnostics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07 Mil.


Biomark Diagnostics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomark Diagnostics (Biomark Diagnostics) Business Description

Traded in Other Exchanges
Address
130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (Biomark Diagnostics) Headlines

No Headlines